Literature DB >> 9135591

Anticoagulation in venous thrombosis.

S Schulman1.   

Abstract

Major studies addressing various aspects of the treatment of deep vein thrombosis are reviewed. It has lately been demonstrated that heparin should be dosed according to body weight and is preferably given as subcutaneous injections twice daily. Alternatively, low-molecular-weight heparins may be given in a fixed dose once daily, which does not require monitoring. Oral anticoagulation should be started concomitantly with heparin and targeted at an international normalized ratio of 2.0-3.0. This treatment should continue for a longer duration than previously accepted, in many cases for 6 months. For patients with contraindications to oral anticoagulation, secondary prophylaxis with a low-molecular-weight heparin is also effective and safe.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9135591      PMCID: PMC1295998          DOI: 10.1177/014107689608901108

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  36 in total

Review 1.  Overview of the management of thrombotic disorders.

Authors:  A S Gallus
Journal:  Semin Thromb Hemost       Date:  1989-04       Impact factor: 4.180

2.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.

Authors:  R D Hull; G E Raskob; J Hirsh; R M Jay; J R Leclerc; W H Geerts; D Rosenbloom; D L Sackett; C Anderson; L Harrison
Journal:  N Engl J Med       Date:  1986-10-30       Impact factor: 91.245

3.  Therapeutic and clinical course of deep vein thrombosis.

Authors:  J O Menzoian; J C Sequeira; J E Doyle; N L Cantelmo; M Nowak; K Tracey; R Zimmerman; P J Mozden
Journal:  Am J Surg       Date:  1983-11       Impact factor: 2.565

4.  Hazards of oral anticoagulants during pregnancy.

Authors:  R E Stevenson; O M Burton; G J Ferlauto; H A Taylor
Journal:  JAMA       Date:  1980-04-18       Impact factor: 56.272

5.  Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis.

Authors:  C I Lagerstedt; C G Olsson; B O Fagher; B W Oqvist; U Albrechtsson
Journal:  Lancet       Date:  1985-09-07       Impact factor: 79.321

6.  The clinical picture of deep vein thrombosis correlated to the frequency of pulmonary embolism.

Authors:  B Lundh; B Fagher
Journal:  Acta Med Scand       Date:  1981

7.  Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.

Authors:  R Hull; J Hirsh; R Jay; C Carter; C England; M Gent; A G Turpie; D McLoughlin; P Dodd; M Thomas; G Raskob; P Ockelford
Journal:  N Engl J Med       Date:  1982-12-30       Impact factor: 91.245

8.  Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.

Authors:  R Hull; T Delmore; C Carter; J Hirsh; E Genton; M Gent; G Turpie; D McLaughlin
Journal:  N Engl J Med       Date:  1982-01-28       Impact factor: 91.245

9.  Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism.

Authors:  A Gallus; J Jackaman; J Tillett; W Mills; A Wycherley
Journal:  Lancet       Date:  1986-12-06       Impact factor: 79.321

10.  Intensive initial oral anticoagulation and shorter heparin treatment in deep vein thrombosis.

Authors:  S Schulman; D Lockner; K Bergström; M Blombäck
Journal:  Thromb Haemost       Date:  1984-12-29       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.